The Optogenetic Option
Optogenetics holds the potential of reversing blindness in retinal disease – but how far has the field come, and who are the key players?
Irv Arons |
At a Glance
- Optogenetics, a technique that originated in neuroscience research, allows neuronal activity to be controlled with light – and potentially bypass damaged photoreceptors to help partially restore vision in those with retinal degenerative disease
- Many of the methods under development are now poised to move to the clinical trial stage, with some prototype manufacturers working towards FDA approval for their devices
- Subretinal implants, biomimetic goggles and programmable computer chips are among the devices that may soon work with optogenetic methods to restore vision in patients with photoreceptor damage
- Photoreceptor rejuvenation or regeneration may remain the most direct path to recovering vision, but photopharmacological switches, retinal prostheses and optogenetics continue to evolve
In the battle to restore vision for those with lost or damaged photoreceptors, progress is being made on many fronts. I have previously described the possibility of reversing blindness by regenerating retinal photoreceptors (1). But there is another promising approach – optogenetics. There are a number of universities and companies currently working in this field, and in this article I will attempt to summarize the current state of research and detail how close we are to human trials of optogenetics-based techniques for restoring lost vision.
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.